Literature DB >> 25917225

Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy.

Angela C Gauthier1, Richard H Mattson2.   

Abstract

Clobazam is an oral 1,5-benzodiazepine used worldwide for the treatment of many types of epilepsies, although it is currently only approved for Lennox-Gastaut syndrome in the USA. This anticonvulsant and anxiolytic therapeutic has repeatedly demonstrated great efficacy and a high safety profile in refractory epilepsy as well as in a few monotherapy trials in both children and adults. Clobazam allosterically activates the GABAA receptor, and it binds less to subunits that mediate sedative effects than other benzodiazepines. It acts quickly, maintaining a therapeutic effect for a long duration due to its active metabolite, N-desmethylclobazam. Dosage is between 5 mg and 40 mg a day, depending on patient weight, efficacy, and tolerability. Efficacy tolerance has not been a problem in the best studies. Clobazam has provided many benefits to epileptic patients. It should be used by clinicians early as an adjuvant therapy in the treatment of refractory epilepsy and even considered as monotherapy in a broad spectrum of epilepsy syndromes.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Anticonvulsants; Benzodiazepines; Clobazam; Epilepsy

Mesh:

Substances:

Year:  2015        PMID: 25917225      PMCID: PMC6495194          DOI: 10.1111/cns.12399

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  17 in total

Review 1.  Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults.

Authors:  Linda J Stephen; Martin J Brodie
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

Review 2.  Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.

Authors:  Martin J Brodie
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

3.  Can clinical practice indicator relating to long-acting benzodiazepine use in the elderly be easily generated in a hospital setting?

Authors:  Badria Kadri; Antonio Teixeira; Christelle Duteil; Annabelle Tan; Hélène Barreteau; Christophe Segouin; Pénélope Troude
Journal:  Eur J Clin Pharmacol       Date:  2017-11-16       Impact factor: 2.953

Review 4.  Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide.

Authors:  Martin J Brodie
Journal:  Curr Neurol Neurosci Rep       Date:  2016-09       Impact factor: 5.081

Review 5.  Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.

Authors:  Zhichuan Li; Lanyan Fang; Wenlei Jiang; Myong-Jin Kim; Liang Zhao
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09-19       Impact factor: 5.081

6.  Amelioration of a neurodevelopmental disorder by carbamazepine in a case having a gain-of-function GRIA3 variant.

Authors:  Kohei Hamanaka; Keita Miyoshi; Jia-Hui Sun; Keisuke Hamada; Takao Komatsubara; Ken Saida; Naomi Tsuchida; Yuri Uchiyama; Atsushi Fujita; Takeshi Mizuguchi; Benedicte Gerard; Allan Bayat; Berardo Rinaldi; Mitsuhiro Kato; Jun Tohyama; Kazuhiro Ogata; Yun Stone Shi; Kuniaki Saito; Satoko Miyatake; Naomichi Matsumoto
Journal:  Hum Genet       Date:  2022-01-15       Impact factor: 4.132

7.  Efficacy and Tolerability of Clobazam in Adults With Drug-Refractory Epilepsy.

Authors:  Alisha Jamil; Noah Levinson; Michael Gelfand; Chloe E Hill; Pouya Khankhanian; Kathryn A Davis
Journal:  Neurol Clin Pract       Date:  2021-10

8.  Hypothermia associated with clobazam use in adult epilepsy.

Authors:  Angela C Gauthier; Imran H Quraishi; Richard H Mattson
Journal:  Epilepsy Behav Case Rep       Date:  2016-01-20

Review 9.  Clobazam and Its Use in Epilepsy.

Authors:  Marius Pernea; Alastair G Sutcliffe
Journal:  Pediatr Rep       Date:  2016-06-15

10.  Effects of clobazam for treatment of refractory status epilepticus.

Authors:  Dominik Madžar; Anna Geyer; Ruben U Knappe; Stephanie Gollwitzer; Joji B Kuramatsu; Stefan T Gerner; Hajo M Hamer; Hagen B Huttner
Journal:  BMC Neurol       Date:  2016-10-21       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.